This study is in progress, not accepting new patients

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

a study on Mesothelioma Astrocytoma Glioblastoma Glioma Kidney Cancer Renal Cell Carcinoma Lung Cancer Non-Small Cell Lung Cancer Skin Cancer/Melanoma Pancreatic Ductal Adenocarcinoma Stomach Cancer Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Cholangiocarcinoma Breast Cancer Ovarian Cancer Cervical Cancer Endocervical Cancer Colorectal Cancer Esophageal Cancer Solid Tumor Carcinoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Joel Hecht (ucla)

Description

Summary

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Official Title

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Keywords

Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer, Carcinoma, Pembrolizumab, NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)

Eligibility

You can join if…

Open to people ages 18 years and up

  • Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
  • Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
  • Adequate bone marrow, kidney and liver function.
  • Performance status of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.

You CAN'T join if...

  • Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.

Locations

  • NGM Clinical Study Site
    Santa Monica' California 90404 United States
  • NGM Clinical Study Site
    Newport Beach California 92663 United States
  • NGM Clinical Study Site
    Los Angeles California 90033 United States

Lead Scientist at University of California Health

  • Joel Hecht (ucla)
    Dr. Joel R. Hecht holds the Carol and Saul Rosenzweig Endowed Chair for Cancer Therapies Development.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
NGM Biopharmaceuticals, Inc
ID
NCT04913337
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 179 study participants
Last Updated